Market Cap 43.31M
Revenue (ttm) 29.62M
Net Income (ttm) -47.58M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -160.63%
Debt to Equity Ratio -0.36
Volume 14,300
Avg Vol 36,724
Day's Range N/A - N/A
Shares Out 4.04M
Stochastic %K 36%
Beta 0.76
Analysts Sell
Price Target $43.00

Company Profile

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 978 1200
Fax: 415 978 1902
Address:
350 Bay Street, Suite 10 #6009, San Francisco, United States
ARKADIY_PARAVOZOV
ARKADIY_PARAVOZOV Oct. 25 at 7:48 AM
$FGEN Procyanidin displayed a synergistic effect with roxadustat on renal anemia in mice https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1678846/abstract
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 25 at 2:05 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $FGEN Current Share Price: $10.88 Contracts: $FGEN January 15, 2027 $2 Calls Scale in: $0.21- $0.26 Scale out: $0.33-$0.43 Can Easily Capture: 60% ROI Blended DTE: 449 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
mjtwins16
mjtwins16 Oct. 23 at 6:27 PM
$FGEN https://pubmed.ncbi.nlm.nih.gov/41079599/?utm_source=FeedFetcher&utm_medium=rss&utm_campaign=None&utm_content=0x09UMLZ1ZyMLjbskVJ3kd6MHfZTZyaCGRc7NzobTEJ&fc=None&ff=20251023004005&v=2.18.0.post22+67771e2
0 · Reply
mjtwins16
mjtwins16 Oct. 23 at 6:26 PM
0 · Reply
AceInTheHole18
AceInTheHole18 Oct. 23 at 6:13 PM
$BCTX $FGEN game on!
0 · Reply
MaxMiamiFl
MaxMiamiFl Oct. 23 at 5:05 PM
0 · Reply
ARKADIY_PARAVOZOV
ARKADIY_PARAVOZOV Oct. 23 at 3:04 PM
$FGEN in an hour and a half of trading, the volume of shares is 279 pieces :). Everyone is waiting for something.
1 · Reply
ARKADIY_PARAVOZOV
ARKADIY_PARAVOZOV Oct. 23 at 9:17 AM
$FGEN https://www.kingnet.com.tw/news/single?newId=49293
0 · Reply
ARKADIY_PARAVOZOV
ARKADIY_PARAVOZOV Oct. 23 at 9:14 AM
$FGEN https://pubmed.ncbi.nlm.nih.gov/41079599/
0 · Reply
Value10
Value10 Oct. 22 at 2:36 AM
$FGEN SEC Earnings Date for FGEN has not been announced, however it is usually the 1st week in November. I would expect some guidance at that time… especially since there now only 2 drugs, no office space, a P.O. Box, little debt… and $150 million in Cash. They may not give it away entirely, but we should get some idea of where we are going.
0 · Reply
Latest News on FGEN
FibroGen, Inc. (FGEN) Q2 2025 Earnings Call Transcript

Aug 11, 2025, 11:55 PM EDT - 2 months ago

FibroGen, Inc. (FGEN) Q2 2025 Earnings Call Transcript


FibroGen to Report Second Quarter 2025 Financial Results

Aug 4, 2025, 4:02 PM EDT - 2 months ago

FibroGen to Report Second Quarter 2025 Financial Results


FibroGen Announces 1-for-25 Reverse Stock Split

Jun 12, 2025, 4:02 PM EDT - 4 months ago

FibroGen Announces 1-for-25 Reverse Stock Split


FibroGen, Inc. (FGEN) Q1 2025 Earnings Call Transcript

May 12, 2025, 10:31 PM EDT - 5 months ago

FibroGen, Inc. (FGEN) Q1 2025 Earnings Call Transcript


FibroGen to Report First Quarter 2025 Financial Results

May 5, 2025, 4:05 PM EDT - 6 months ago

FibroGen to Report First Quarter 2025 Financial Results


FibroGen, Inc. (FGEN) Q4 2024 Earnings Call Transcript

Mar 17, 2025, 8:18 PM EDT - 7 months ago

FibroGen, Inc. (FGEN) Q4 2024 Earnings Call Transcript


FibroGen Appoints David DeLucia as Chief Financial Officer

Dec 16, 2024, 8:05 AM EST - 11 months ago

FibroGen Appoints David DeLucia as Chief Financial Officer


FibroGen Reports Third Quarter 2024 Financial Results

Nov 12, 2024, 4:05 PM EST - 1 year ago

FibroGen Reports Third Quarter 2024 Financial Results


FibroGen to Report Third Quarter 2024 Financial Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

FibroGen to Report Third Quarter 2024 Financial Results


FibroGen, Inc. (FGEN) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 11:32 AM EDT - 1 year ago

FibroGen, Inc. (FGEN) Q2 2024 Earnings Call Transcript


FibroGen to Report Second Quarter 2024 Financial Results

Jul 30, 2024, 4:07 PM EDT - 1 year ago

FibroGen to Report Second Quarter 2024 Financial Results


FibroGen to Participate in Upcoming Investor Conferences

May 7, 2024, 7:00 AM EDT - 1 year ago

FibroGen to Participate in Upcoming Investor Conferences


FibroGen, Inc. (FGEN) Q1 2024 Earnings Call Transcript

May 6, 2024, 10:31 PM EDT - 1 year ago

FibroGen, Inc. (FGEN) Q1 2024 Earnings Call Transcript


FibroGen Reports First Quarter 2024 Financial Results

May 6, 2024, 4:02 PM EDT - 1 year ago

FibroGen Reports First Quarter 2024 Financial Results


FibroGen to Report First Quarter 2024 Financial Results

Apr 29, 2024, 7:00 AM EDT - 1 year ago

FibroGen to Report First Quarter 2024 Financial Results


FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

Mar 11, 2024, 7:00 AM EDT - 1 year ago

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer


FibroGen, Inc. (FGEN) Q4 2023 Earnings Call Transcript

Feb 26, 2024, 11:44 PM EST - 1 year ago

FibroGen, Inc. (FGEN) Q4 2023 Earnings Call Transcript


FibroGen regains rights to anemia drug from AstraZeneca

Feb 26, 2024, 4:18 PM EST - 1 year ago

FibroGen regains rights to anemia drug from AstraZeneca

AZN


FibroGen, Inc. (FGEN) Q3 2023 Earnings Call Transcript

Nov 6, 2023, 8:30 PM EST - 2 years ago

FibroGen, Inc. (FGEN) Q3 2023 Earnings Call Transcript


FibroGen Reports Third Quarter 2023 Financial Results

Nov 6, 2023, 4:01 PM EST - 2 years ago

FibroGen Reports Third Quarter 2023 Financial Results


ARKADIY_PARAVOZOV
ARKADIY_PARAVOZOV Oct. 25 at 7:48 AM
$FGEN Procyanidin displayed a synergistic effect with roxadustat on renal anemia in mice https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1678846/abstract
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 25 at 2:05 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $FGEN Current Share Price: $10.88 Contracts: $FGEN January 15, 2027 $2 Calls Scale in: $0.21- $0.26 Scale out: $0.33-$0.43 Can Easily Capture: 60% ROI Blended DTE: 449 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
mjtwins16
mjtwins16 Oct. 23 at 6:27 PM
$FGEN https://pubmed.ncbi.nlm.nih.gov/41079599/?utm_source=FeedFetcher&utm_medium=rss&utm_campaign=None&utm_content=0x09UMLZ1ZyMLjbskVJ3kd6MHfZTZyaCGRc7NzobTEJ&fc=None&ff=20251023004005&v=2.18.0.post22+67771e2
0 · Reply
mjtwins16
mjtwins16 Oct. 23 at 6:26 PM
0 · Reply
AceInTheHole18
AceInTheHole18 Oct. 23 at 6:13 PM
$BCTX $FGEN game on!
0 · Reply
MaxMiamiFl
MaxMiamiFl Oct. 23 at 5:05 PM
0 · Reply
ARKADIY_PARAVOZOV
ARKADIY_PARAVOZOV Oct. 23 at 3:04 PM
$FGEN in an hour and a half of trading, the volume of shares is 279 pieces :). Everyone is waiting for something.
1 · Reply
ARKADIY_PARAVOZOV
ARKADIY_PARAVOZOV Oct. 23 at 9:17 AM
$FGEN https://www.kingnet.com.tw/news/single?newId=49293
0 · Reply
ARKADIY_PARAVOZOV
ARKADIY_PARAVOZOV Oct. 23 at 9:14 AM
$FGEN https://pubmed.ncbi.nlm.nih.gov/41079599/
0 · Reply
Value10
Value10 Oct. 22 at 2:36 AM
$FGEN SEC Earnings Date for FGEN has not been announced, however it is usually the 1st week in November. I would expect some guidance at that time… especially since there now only 2 drugs, no office space, a P.O. Box, little debt… and $150 million in Cash. They may not give it away entirely, but we should get some idea of where we are going.
0 · Reply
NolAsrtormZ
NolAsrtormZ Oct. 21 at 4:19 PM
$GRI only a few tickers know how much iPf data is worth. $PLRX lost 900 million market cap for ipf data $TVRD lost 300 million market cap for ipf data $FGEN went from $16 to $3.00 on ipf data Gri market cap. 5 million
0 · Reply
AceInTheHole18
AceInTheHole18 Oct. 21 at 1:51 PM
$BCTX $FGEN shining stars
0 · Reply
MaxMiamiFl
MaxMiamiFl Oct. 21 at 1:09 PM
$FGEN $14 +..........that's all I want lol
1 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Oct. 21 at 3:26 AM
$FGEN Let’s Gooooooo!
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 21 at 12:09 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $FGEN Current Share Price: $10.38 Contracts: $FGEN January 15, 2027 $2 Calls Scale in: $0.21- $0.26 Scale out: $0.33-$0.43 Can Easily Capture: 60% ROI Blended DTE: 453 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
AceInTheHole18
AceInTheHole18 Oct. 20 at 6:54 PM
$FGEN loading up the truck!
1 · Reply
MaxMiamiFl
MaxMiamiFl Oct. 20 at 12:23 PM
0 · Reply
NolAsrtormZ
NolAsrtormZ Oct. 20 at 11:52 AM
$GRI .... $TVRD failed iPf data lost 300 million market cap $PLRX discontinued ipf data lost 900 million market cap $FGEN failed ipf data went from $16 to $3 Billion $$$ market cap for ipf data =
0 · Reply
MaxMiamiFl
MaxMiamiFl Oct. 19 at 7:45 PM
$FGEN let's have a solid green week 💪
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 18 at 3:11 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $FGEN Current Share Price: $10.77 Contracts: $FGEN January 15, 2027 $2 Calls Scale in: $0.21- $0.26 Scale out: $0.33-$0.43 Can Easily Capture: 60% ROI Blended DTE: 455 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
ARKADIY_PARAVOZOV
ARKADIY_PARAVOZOV Oct. 18 at 6:48 AM
$FGEN I’ve shared my thoughts on FibroGen. The text turned out quite lengthy, so I’ve had to post it as an image. Apologies for the English—I used an online translator. I want to emphasize that I’m not trying to impose my views on anyone. This is just my personal hypothesis, based entirely on publicly available information. I have no insider knowledge whatsoever—and of course, I could be wrong...
1 · Reply
ARKADIY_PARAVOZOV
ARKADIY_PARAVOZOV Oct. 17 at 7:22 AM
$FGEN In my opinion, now is the right time to sell the company and for its buyer. The main thing is to agree on an acceptable price for everyone. If I were a director, that's what I would do.
2 · Reply